Yongheng Chen

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 58

Top Topics

Structural Basis

Top Venues

Cell death & disease

Communications chemistry

Pharmaceuticals (Basel, Switzerland)

Journal of medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Yun Li, Xiangqian Zhang, Na Liu, Ruijie Liu, Wuming Zhang, Lin Chen, Yongheng Chen
RNF166 promotes colorectal cancer progression by recognizing and destabilizing poly-ADP-ribosylated angiomotins. Cell death & disease 15 (3) (2024)
Jingzhi Li, Ming Guo, Chia-Lin Chen, Zhuchu Chen, Ying Fu, Yongheng Chen
Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. Cell death & disease 15 (1) (2024)
Jingzhi Li, Ming Guo, Chia-Lin Chen, Zhuchu Chen, Ying Fu, Yongheng Chen
Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. Cell death & disease 15 (1) (2024)
Xuan Zheng, Zhiwen Chen, Ming Guo, Hong Liang, Xiaojuan Song, Yiling Liu, Zhenling Liao, Yan Zhang, Jing Guo, Yang Zhou, Zhi-Min Zhang, Zhengchao Tu, Ye Zhang, Yongheng Chen, Zhang Zhang, Xiaoyun Lu
Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations. ACS pharmacology & translational science 7 (5) (2024)
Fang Yang, Qianmeng Lin, Xiaojuan Song, Huisi Huang, Xiaojuan Chen, Jianwen Tan, Yun Li, Yang Zhou, Zhengchao Tu, Hongli Du, Zhi-Min Zhang, Raquel Ortega, Xiaojing Lin, Adam V Patterson, Jeff B Smaill, Yongheng Chen, Xiaoyun Lu
Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity. Journal of medicinal chemistry 67 (4) (2024)
Yalan Deng, Liqing Lu, Dandan Zhu, Huajun Zhang, Ying Fu, Yuying Tan, Xuemei Tan, Ming Guo, Ye Zhang, Heping Yang, Bing Yang, Ting Liu, Yongheng Chen
MafG/MYH9-LCN2 axis promotes liver fibrosis through inhibiting ferroptosis of hepatic stellate cells. Cell death and differentiation (2024)
Shuyan Dai, Liang Guo, Raja Dey, Ming Guo, Xiangqian Zhang, Darren Bates, Justin Cayford, Longying Jiang, Hudie Wei, Zhuchu Chen, Ye Zhang, Lin Chen, Yongheng Chen
Structural insights into the HDAC4-MEF2A-DNA complex and its implication in long-range transcriptional regulation. Nucleic acids research (2024)
Jingzhi Li, Ming Guo, Chia-Lin Chen, Zhuchu Chen, Ying Fu, Yongheng Chen
Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. Cell death & disease 15 (1) (2024)
Xuan Zheng, Zhiwen Chen, Ming Guo, Hong Liang, Xiaojuan Song, Yiling Liu, Zhenling Liao, Yan Zhang, Jing Guo, Yang Zhou, Zhi-Min Zhang, Zhengchao Tu, Ye Zhang, Yongheng Chen, Zhang Zhang, Xiaoyun Lu
Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations. ACS pharmacology & translational science 7 (5) (2024)
Shuyan Dai, Liang Guo, Raja Dey, Ming Guo, Xiangqian Zhang, Darren Bates, Justin Cayford, Longying Jiang, Hudie Wei, Zhuchu Chen, Ye Zhang, Lin Chen, Yongheng Chen
Structural insights into the HDAC4-MEF2A-DNA complex and its implication in long-range transcriptional regulation. Nucleic acids research 52 (5) (2024)
Jingzhi Li, Ming Guo, Chia-Lin Chen, Zhuchu Chen, Ying Fu, Yongheng Chen
Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. Cell death & disease 15 (1) (2024)
Yun Li, Xiangqian Zhang, Na Liu, Ruijie Liu, Wuming Zhang, Lin Chen, Yongheng Chen
RNF166 promotes colorectal cancer progression by recognizing and destabilizing poly-ADP-ribosylated angiomotins. Cell death & disease 15 (3) (2024)
Yalan Deng, Liqing Lu, Dandan Zhu, Huajun Zhang, Ying Fu, Yuying Tan, Xuemei Tan, Ming Guo, Ye Zhang, Heping Yang, Bing Yang, Ting Liu, Yongheng Chen
MafG/MYH9-LCN2 axis promotes liver fibrosis through inhibiting ferroptosis of hepatic stellate cells. Cell death and differentiation 31 (9) (2024)
Qianmeng Lin, Shuyan Dai, Lingzhi Qu, Hang Lin, Ming Guo, Hudie Wei, Yongheng Chen, Xiaojuan Chen
Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R. Communications chemistry 7 (1) (2024)
Jingzhi Li, Ming Guo, Chia-Lin Chen, Zhuchu Chen, Ying Fu, Yongheng Chen
Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. Cell death & disease 15 (1) (2024)
Qianmeng Lin, Shuyan Dai, Lingzhi Qu, Hang Lin, Ming Guo, Hudie Wei, Yongheng Chen, Xiaojuan Chen
Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R. Communications chemistry 7 (1) (2024)
Shuyan Dai, Liang Guo, Raja Dey, Ming Guo, Xiangqian Zhang, Darren Bates, Justin Cayford, Longying Jiang, Hudie Wei, Zhuchu Chen, Ye Zhang, Lin Chen, Yongheng Chen
Structural insights into the HDAC4-MEF2A-DNA complex and its implication in long-range transcriptional regulation. Nucleic acids research 52 (5) (2024)
Fang Yang, Qianmeng Lin, Xiaojuan Song, Huisi Huang, Xiaojuan Chen, Jianwen Tan, Yun Li, Yang Zhou, Zhengchao Tu, Hongli Du, Zhi-Min Zhang, Raquel Ortega, Xiaojing Lin, Adam V Patterson, Jeff B Smaill, Yongheng Chen, Xiaoyun Lu
Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity. Journal of medicinal chemistry 67 (4) (2024)
Shuyan Dai, Liang Guo, Raja Dey, Ming Guo, Xiangqian Zhang, Darren Bates, Justin Cayford, Longying Jiang, Hudie Wei, Zhuchu Chen, Ye Zhang, Lin Chen, Yongheng Chen
Structural insights into the HDAC4-MEF2A-DNA complex and its implication in long-range transcriptional regulation. Nucleic acids research 52 (5) (2024)
Yun Li, Xiangqian Zhang, Na Liu, Ruijie Liu, Wuming Zhang, Lin Chen, Yongheng Chen
RNF166 promotes colorectal cancer progression by recognizing and destabilizing poly-ADP-ribosylated angiomotins. Cell death & disease 15 (3) (2024)
Fang Yang, Qianmeng Lin, Xiaojuan Song, Huisi Huang, Xiaojuan Chen, Jianwen Tan, Yun Li, Yang Zhou, Zhengchao Tu, Hongli Du, Zhi-Min Zhang, Raquel Ortega, Xiaojing Lin, Adam V Patterson, Jeff B Smaill, Yongheng Chen, Xiaoyun Lu
Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity. Journal of medicinal chemistry (2024)
Hudie Wei, Haolan Wang, Genxin Wang, Lingzhi Qu, Longying Jiang, Shuyan Dai, Xiaojuan Chen, Ye Zhang, Zhuchu Chen, Youjun Li, Ming Guo, Yongheng Chen
Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity. Nature communications 14 (1) (2023)
Zhe Cheng, Huichao Huang, Maoyu Li, Xujun Liang, Yuying Tan, Yongheng Chen
Lactylation-Related Gene Signature Effectively Predicts Prognosis and Treatment Responsiveness in Hepatocellular Carcinoma. Pharmaceuticals (Basel, Switzerland) 16 (5) (2023)
Xiangqian Zhang, Yunfan Zhang, Xiaomei Gao, Ye Zhang, Yongheng Chen
Integrated Single-Cell and Transcriptome Sequencing Analyses Identify Dipeptidase 2 as an Immune-Associated Prognostic Biomarker for Lung Adenocarcinoma. Pharmaceuticals (Basel, Switzerland) 16 (6) (2023)
Haolan Wang, Ming Guo, Hudie Wei, Yongheng Chen
Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal transduction and targeted therapy 8 (1) (2023)
Zhe Cheng, Yongheng Chen, Huichao Huang
Identification and Validation of a Novel Prognostic Signature Based on Ferroptosis-Related Genes in Ovarian Cancer. Vaccines 11 (2) (2023)
Haolan Wang, Ming Guo, Hudie Wei, Yongheng Chen
Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal transduction and targeted therapy 8 (1) (2023)
Zhe Cheng, Yongheng Chen, Huichao Huang
Identification and Validation of a Novel Prognostic Signature Based on Ferroptosis-Related Genes in Ovarian Cancer. Vaccines 11 (2) (2023)
Xiangqian Zhang, Yunfan Zhang, Xiaomei Gao, Ye Zhang, Yongheng Chen
Integrated Single-Cell and Transcriptome Sequencing Analyses Identify Dipeptidase 2 as an Immune-Associated Prognostic Biomarker for Lung Adenocarcinoma. Pharmaceuticals (Basel, Switzerland) 16 (6) (2023)
Xiangqian Zhang, Yun Li, Yongheng Chen
Development of a Comprehensive Gene Signature Linking Hypoxia, Glycolysis, Lactylation, and Metabolomic Insights in Gastric Cancer through the Integration of Bulk and Single-Cell RNA-Seq Data. Biomedicines 11 (11) (2023)
Haolan Wang, Ming Guo, Hudie Wei, Yongheng Chen
Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal transduction and targeted therapy 8 (1) (2023)
Bing Yang, Jing Zhang, Jiaohong Wang, Wei Fan, Lucía Barbier-Torres, Xi Yang, Monica Anne R Justo, Ting Liu, Yongheng Chen, Justin A Steggerda, Komal Ramani, Shelly C Lu, Heping Yang
CSNK2A1-mediated MAX phosphorylation upregulates HMGB1 and IL-6 expression in cholangiocarcinoma progression. Hepatology communications 7 (7) (2023)
Haolan Wang, Ming Guo, Hudie Wei, Yongheng Chen
Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal transduction and targeted therapy 8 (1) (2023)
Lingzhi Qu, Xiaojuan Chen, Hudie Wei, Ming Guo, Shuyan Dai, Longying Jiang, Jun Li, Sitong Yue, Zhuchu Chen, Yongheng Chen
Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. Communications chemistry 5 (1) (2022)
Qianmeng Lin, Xiaojuan Chen, Lingzhi Qu, Ming Guo, Hudie Wei, Shuyan Dai, Longying Jiang, Yongheng Chen
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. Communications chemistry 5 (1) (2022)
Chaofan Wang, Jie Li, Lingzhi Qu, Xia Tang, Xiaojuan Song, Fang Yang, Xiaojuan Chen, Qianmeng Lin, Weibin Lin, Yang Zhou, ZhengChao Tu, Yongheng Chen, Zhang Zhang, Xiaoyun Lu
Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment. Journal of medicinal chemistry 65 (22) (2022)
Qianmeng Lin, Xiaojuan Chen, Lingzhi Qu, Ming Guo, Hudie Wei, Shuyan Dai, Longying Jiang, Yongheng Chen
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. Communications chemistry 5 (1) (2022)
Shuyan Dai, Lingzhi Qu, Jun Li, Ye Zhang, Longying Jiang, Hudie Wei, Ming Guo, Xiaojuan Chen, Yongheng Chen
Structural insight into the ligand binding mechanism of aryl hydrocarbon receptor. Nature communications 13 (1) (2022)
Lingzhi Qu, Xiaojuan Chen, Hudie Wei, Ming Guo, Shuyan Dai, Longying Jiang, Jun Li, Sitong Yue, Zhuchu Chen, Yongheng Chen
Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. Communications chemistry 5 (1) (2022)
Huichao Huang, Fangling Huang, Xujun Liang, Ying Fu, Zhe Cheng, Yan Huang, Zhuchu Chen, Yankun Duan, Yongheng Chen
Afatinib Reverses EMT via Inhibiting CD44-Stat3 Axis to Promote Radiosensitivity in Nasopharyngeal Carcinoma. Pharmaceuticals (Basel, Switzerland) 16 (1) (2022)
Fang Yang, Xiaojuan Chen, Xiaojuan Song, Raquel Ortega, Xiaojing Lin, Wuqing Deng, Jing Guo, Zhengchao Tu, Adam V Patterson, Jeff B Smaill, Yongheng Chen, Xiaoyun Lu
Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2- b ]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors. Journal of medicinal chemistry 65 (21) (2022)
Huajun Zhang, Wuyang Zhang, Longying Jiang, Yongheng Chen
Recent advances in systemic therapy for hepatocellular carcinoma. Biomarker research 10 (1) (2022)
Liqing Lu, Ye Zhang, Xuemei Tan, Yulia Merkher, Sergey Leonov, Li Zhu, Yalan Deng, Huajun Zhang, Dandan Zhu, Yuying Tan, Ying Fu, Ting Liu, Yongheng Chen
Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer. Cell death discovery 8 (1) (2022)
Xiaojuan Chen, Huiliang Li, Qianmeng Lin, Shuyan Dai, Sitong Yue, Lingzhi Qu, Maoyu Li, Ming Guo, Hudie Wei, Jun Li, Longying Jiang, Guangyu Xu, Yongheng Chen
Structure-based design of a dual-warhead covalent inhibitor of FGFR4. Communications chemistry 5 (1) (2022)
Huichao Huang, Fangling Huang, Xujun Liang, Ying Fu, Zhe Cheng, Yan Huang, Zhuchu Chen, Yankun Duan, Yongheng Chen
Afatinib Reverses EMT via Inhibiting CD44-Stat3 Axis to Promote Radiosensitivity in Nasopharyngeal Carcinoma. Pharmaceuticals (Basel, Switzerland) 16 (1) (2022)
Xiaojuan Chen, Huiliang Li, Qianmeng Lin, Shuyan Dai, Sitong Yue, Lingzhi Qu, Maoyu Li, Ming Guo, Hudie Wei, Jun Li, Longying Jiang, Guangyu Xu, Yongheng Chen
Structure-based design of a dual-warhead covalent inhibitor of FGFR4. Communications chemistry 5 (1) (2022)
Min Shao, Xiaojuan Chen, Fang Yang, Xiaojuan Song, Yang Zhou, Qianmeng Lin, Ying Fu, Raquel Ortega, Xiaojing Lin, Zhengchao Tu, Adam V Patterson, Jeff B Smaill, Yongheng Chen, Xiaoyun Lu
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4. Journal of medicinal chemistry 65 (6) (2022)
Huichao Huang, Fangling Huang, Xujun Liang, Ying Fu, Zhe Cheng, Yan Huang, Zhuchu Chen, Yankun Duan, Yongheng Chen
Afatinib Reverses EMT via Inhibiting CD44-Stat3 Axis to Promote Radiosensitivity in Nasopharyngeal Carcinoma. Pharmaceuticals (Basel, Switzerland) 16 (1) (2022)
Haolan Wang, Ming Guo, Hudie Wei, Yongheng Chen
Targeting MCL-1 in cancer: current status and perspectives. Journal of hematology & oncology 14 (1) (2021)
Zhe Cheng, Maoyu Li, Raja Dey, Yongheng Chen
Nanomaterials for cancer therapy: current progress and perspectives. Journal of hematology & oncology 14 (1) (2021)
Haolan Wang, Liqing Lu, Xujun Liang, Yongheng Chen
Identification of prognostic genes in the pancreatic adenocarcinoma immune microenvironment by integrated bioinformatics analysis. Cancer immunology, immunotherapy : CII (2021)
Hudie Wei, Lingzhi Qu, Shuyan Dai, Yun Li, Haolan Wang, Yilu Feng, Xiaojuan Chen, Longying Jiang, Ming Guo, Jun Li, Zhuchu Chen, Lin Chen, Ye Zhang, Yongheng Chen
Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis. Nature communications 12 (1) (2021)
Shuyan Dai, Linzhi Qu, Jun Li, Yongheng Chen
Toward a mechanistic understanding of DNA binding by forkhead transcription factors and its perturbation by pathogenic mutations. Nucleic acids research 49 (18) (2021)
Ye Zhang, Shuang Zhao, Ying Fu, Lu Yan, Yilu Feng, Yaqi Chen, Yijia Wu, Yalan Deng, Guiying Zhang, Zhuchu Chen, Yongheng Chen, Ting Liu
Computational repositioning of dimethyl fumarate for treating alcoholic liver disease. Cell death & disease 11 (8) (2020)
Yilu Feng, Ye Zhang, Yi Cai, Ruijie Liu, Miaolong Lu, Tangzhiming Li, Ying Fu, Ming Guo, Huichao Huang, Yifu Ou, Yongheng Chen
A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma. Cell death & disease 11 (2) (2020)
Ye Zhang, Maoyu Li, Xiaomei Gao, Yongheng Chen, Ting Liu
Nanotechnology in cancer diagnosis: progress, challenges and opportunities. Journal of hematology & oncology 12 (1) (2019)
Shuyan Dai, Zhan Zhou, Zhuchu Chen, Guangyu Xu, Yongheng Chen
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells 8 (6) (2019)
Jun Li, Ana Carolina Dantas Machado, Ming Guo, Jared M Sagendorf, Zhan Zhou, Longying Jiang, Xiaojuan Chen, Daichao Wu, Lingzhi Qu, Zhuchu Chen, Lin Chen, Remo Rohs, Yongheng Chen
Structure of the Forkhead Domain of FOXA2 Bound to a Complete DNA Consensus Site. Biochemistry 56 (29) (2017)